Jeil Pharma Holdings Inc (KRX:002620)
South Korea
· Delayed Price · Currency is KRW 7,670.00
-200.00 (-2.54%)
At close: Mar 26, 2025, 3:30 PM KST
Jeil Pharma Holdings Revenue
In the year 2024, Jeil Pharma Holdings had annual revenue of 779.82B KRW, down -3.01%. Jeil Pharma Holdings had revenue of 203.97B in the quarter ending December 31, 2024, with 0.51% growth.
Revenue
779.82B
Revenue Growth
-3.01%
P/S Ratio
0.15
Revenue / Employee
22.28B
Employees
35
Market Cap
120.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 779.82B | -24.22B | -3.01% |
| Dec 31, 2023 | 804.04B | 11.08B | 1.40% |
| Dec 31, 2022 | 792.96B | 30.40B | 3.99% |
| Dec 31, 2021 | 762.57B | 571.30M | 0.07% |
| Dec 31, 2020 | 762.00B | 30.19B | 4.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |